A method of treating liver inflammation in an individual caused by excess fat deposition, sometimes called “fatty liver disease”, which may be caused by metabolic syndrome, insulin resistance, or gut microbial dysbiosis, and which may lead to the serious and potentially life-threatening condition of non-alcoholic steatohepatitis (NASH) comprising the steps of preparing a composition composed of an all-D amino acid peptide and a pharmaceutically acceptable carrier. The D peptide has the general structure: A-B-C-D-E in whichA is Ser, Thr, Asn, Glu, Ile.B is Ser, Thr, Asp, Asn,C is Thr, Ser, Asn, Arg, Lys, Trp,D is Tyr, andE is Thr, Ser, Arg, Gly.And wherein all amino acids in the D peptide are the D stereoisomeric configuration and said peptide composition is administered in a therapeutically effective dose wherein said composition acts to suppress inflammation underlying steatohepatitis. The D peptide may be esterified, glycosylated, or amidated at E to enhance tissue distribution by promoting egress from the circulation and penetration into the liver.
